Semaglutide rankingsTirzepatide rankingsState guidesJournalHow we rank
Source transparency

GLP-1 Evidence Library & Source Log

This page centralizes the official sources, safety references, regulatory pages and editorial source types used across Undoubtify semaglutide and tirzepatide comparisons.

Primary source hierarchy

For medical and regulatory statements, Undoubtify prioritizes FDA pages, prescribing information, clinical trial publications, pharmacy verification resources, and dated provider disclosures. Marketing pages and customer reviews are treated as lower-confidence signals unless independently verifiable.

FDA GLP-1 compounding policy updateshttps://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilizeFDA proposed 503B bulks exclusion for semaglutide, tirzepatide and liraglutidehttps://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-listFDA Orange Book and drug labelshttps://www.accessdata.fda.gov/scripts/cder/daf/LegitScript certification standardshttps://www.legitscript.com/certification/healthcare/National Association of Boards of Pharmacy pharmacy verificationhttps://safe.pharmacy/

How we use sources

  • Regulatory caveats are sourced to official FDA pages where possible.
  • Provider rankings are editorial comparisons, not medical recommendations.
  • Customer reviews are used as qualitative themes, not clinical proof.
  • Pricing should be rechecked monthly because offers change quickly.
  • Compounded medications are clearly distinguished from FDA-approved brand-name products.